Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

The Lancet Gastroenterology & Hepatology · Published 2026-06-24 · DOI 10.1016/s2468-1253(26)00116-0

Free full text

Authors (68)

Nirmala P Gonsalves, Evan S Dellon, Kara L Kliewer, Tetsuo Shoda, Regina Yearout, Seema S Aceves, Nicoleta C Arva, John A Besse, Julie M Caldwell, Mirna Chehade, Amaziah Coleman, Margaret H Collins, Sara Anvari, Gary W Falk, Sandeep K Gupta, Girish Hiremath, David A Katzka, Paneez Khoury, John Leung, Calies Menard-Katcher, Paul Menard-Katcher, Kathryn A Peterson, Maria A Pletneva, Amanda K Rudman Spergel, Jonathan M Spergel, Tatyana Vaysman, Joshua B Wechsler, Benjamin L Wright, Guang-Yu Yang, Xue Zhang, Meijian Zhou, Ashish Bansal, Bram P Raphael, Amr Radwan, Jennifer Maloney, Antonio Martin, Yamo Deniz, Glenn T Furuta, Lisa J Martin, Marc E Rothenberg, Justin Schwartz, Pablo Abonia, Philip Putnam, Sandy Durrani, Scott Bolton, Vincent Mukkada, Nathalie Nguyen, Amanda Muir, Antonella Cianferoni, Asim Maqbool, Bridget Godwin, Gayle Diamond, Rahul Datta, Melanie Ruffner, Samantha Fish, Arunjot Singh, Ronen Stein, Terri Brown-Whitehorn, Alexandra Strauss, Kristle Lynch, Anthony Olive, Eric Chiou, Kathleen Pitts, Melissa Hearrell, Carla Davis, Amiko Uchida, Andrew Gawron, John Fang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Gonsalves, N., Dellon, E., Kliewer, K., et al. (2026). Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(26)00116-0

Related articles